Samantha McClellan
she/her/hers
Research
Publications
2026
STIM1 and endoplasmic reticulum–plasma membrane contact sites oscillate independently of calcium-induced calcium release
Xiong D, Tong C, Fung S, McClellan S, Yang Y, Yong J, Wu M. STIM1 and endoplasmic reticulum–plasma membrane contact sites oscillate independently of calcium-induced calcium release. Open Biology 2026, 16: 250220. PMID: 41844235, DOI: 10.1098/rsob.250220.Peer-Reviewed Original ResearchThis study investigates how STIM1 and ER-plasma membrane contact sites oscillate independently of calcium signaling, revealing a new mechanism regulating calcium dynamics in cells.
2025
Restoration of LAT activity improves CAR T cell sensitivity and persistence in response to antigen-low acute lymphoblastic leukemia
Pham-Danis C, Novak A, Danis E, McClellan S, Leach L, Yarnell M, Ebmeier C, Tasian S, Kohler M. Restoration of LAT activity improves CAR T cell sensitivity and persistence in response to antigen-low acute lymphoblastic leukemia. Cancer Cell 2025, 43: 482-502.e9. PMID: 40068599, PMCID: PMC12002840, DOI: 10.1016/j.ccell.2025.02.008.Peer-Reviewed Original Research
2024
Co-targeting of the thymic stromal lymphopoietin receptor to decrease immunotherapeutic resistance in CRLF2-rearranged Ph-like and Down syndrome acute lymphoblastic leukemia
Balestra T, Niswander L, Bagashev A, Loftus J, Ross S, Chen R, McClellan S, Junco J, Bárcenas López D, Rabin K, Fry T, Tasian S. Co-targeting of the thymic stromal lymphopoietin receptor to decrease immunotherapeutic resistance in CRLF2-rearranged Ph-like and Down syndrome acute lymphoblastic leukemia. Leukemia 2024, 39: 555-567. PMID: 39681640, PMCID: PMC11879877, DOI: 10.1038/s41375-024-02493-3.Peer-Reviewed Original ResearchGilteritinib Augments Preclinical FLT3 and CD19 CAR T Cell Immunotherapy in High-Risk Pediatric Leukemias
Niswander L, McClellan S, Barcenas-Lopez D, Yarnell M, Bhatnagar S, Fry T, Tasian S. Gilteritinib Augments Preclinical FLT3 and CD19 CAR T Cell Immunotherapy in High-Risk Pediatric Leukemias. Blood 2024, 144: 370. DOI: 10.1182/blood-2024-206467.Peer-Reviewed Original ResearchCo-Targeting of the Thymic Stromal Lymphopoietin Receptor to Decrease Immunotherapeutic Resistance in CRLF2-Rearranged Ph-like and Down Syndrome ALL
Balestra T, Niswander L, Bagashev A, Loftus J, Ross S, Chen R, McClellan S, Junco J, Barcenas-Lopez D, Rabin K, Fry T, Tasian S. Co-Targeting of the Thymic Stromal Lymphopoietin Receptor to Decrease Immunotherapeutic Resistance in CRLF2-Rearranged Ph-like and Down Syndrome ALL. Blood 2024, 144: 3424. DOI: 10.1182/blood-2024-208383.Peer-Reviewed Original Research